Akzo Nobel N.V. (AKZA) Earnings Call Transcripts
Akzo Nobel N.V.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Akzo Nobel N.V. reported an adjusted EBITDA of EUR 345 million, exceeding consensus estimates by 7%. Revenue declined 9% year-over-year, primarily due to a 3% negative impact from the divestment of India and a 5% reduction from FX translation. Management maintained its full-year adjusted EBITDA guidance of at least EUR 1.7 billion, signaling confidence despite ongoing raw material inflation and geopolitical uncertainties.
Reported metrics
| Metric | Value |
|---|---|
| Adjusted EBITDA | EUR 345 million (beat) |
| Revenue | EUR 2.4 billion (miss) |
| Adjusted EBITDA Margin | 14.5% (positive) |
| Free Cash Flow | EUR -144 million (positive) |
| Leverage Ratio | 2x (inline) |
| Volume Change | -1% (negative) |
Guidance from management
Management maintained its full-year adjusted EBITDA target of at least EUR 1.7 billion, indicating confidence in their cost control measures despite inflationary pressures.
What management said
Yes. Thank you, Greg. Before we start the Q&A session, I would like to draw your attention to the upcoming events shown on Slide 10. Our AGM that will be held tomorrow, April 23, the ex-dividend date on our 2025 final dividend, April 27, and the record date is April 28, followed by payment on May 6. This concludes the formal presentation, and we'll be happy to address your questions. [Operator Instructions] Operato...
Yes, on the pricing dynamics and maybe a few points to make. First of all, this is really a very abrupt price increase. But of course, there is a different picture per region and also per business or per business segment. So we use differentiated pricing, of course, in that context. And on your question on lead time, what you see in general that in Asia and particularly in China, supply chains are significantly sho...
What analysts pressed on
Analysts expressed concerns regarding potential demand erosion due to inflation and geopolitical tensions. There were questions about the effectiveness of the pricing strategy and the impact of raw material costs on future performance.
Main topics on the call
- Strong Margin Expansion — The adjusted EBITDA margin improved to 14.5%, up 80 basis points year-over-year, driven by disciplined pricing and cost actions. Management stated, "This marks the fourth quarter of margin expansion year-on-year, driven ...
- Volume Declines — Organic sales were down 1% year-on-year, with volumes declining 1% across the board. Management noted, "We saw strong growth across Asia and South America, while North America and Europe remain slow," indicating mixed re...
- Pricing Strategy Amid Inflation — Management announced price increases ranging from mid-single digits to low teens to offset high-teens raw material inflation. They emphasized, "We believe we have the track record to back our confidence" in passing throu...
- Ongoing Divestment Strategy — The sale of the Deco business in Pakistan was signed at 14x EBITDA, reinforcing management's commitment to divest non-core assets. They remarked, "This is another proof point after India that Deco assets are valuable, pa...
Read the full Akzo Nobel N.V. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Akzo Nobel N.V.
Akzo Nobel N.V. (AKZA) is a publicly listed company in the Chemicals industry, within the Materials sector. It trades on ENXTAM and is based in NL. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 36 calls on record spanning February 12, 2020 to July 22, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 36 Akzo Nobel N.V. earnings call transcripts on record, spanning February 12, 2020 to July 22, 2026. Based on this history, Akzo Nobel N.V. reports quarterly. The most recent call on file is dated July 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.